CBD Life Sciences Inc. (CBDL) Announces New Manufacturing Deal With A Columbian Company

Rhea-AI Summary

CBD Life Sciences has secured a strategic manufacturing partnership with Thallos, a Colombian company, to produce high-potency CBD products for the South American market. The deal positions CBDL to tap into the $4.9 billion Latin American CBD market.

Under the agreement, CBDL will manufacture Thallos' product line including:

• 2,000mg Pain Cream Salve (Mint and Cinnamon varieties)
• 2,000mg CBD Tincture

Production will take place at CBDL's U.S. facilities, offering Thallos a solution to bypass tariff and regulatory challenges for CBD imports. CEO Lisa Nelson describes the partnership as a "game-changer," positioning CBDL as a key player in the global CBD supply chain. The deal promises recurring revenue streams and strengthens CBDL's international market presence.

Positive

• New manufacturing deal with Thallos to produce high-potency CBD products
• Access to $4.9B Latin American CBD market by 2028
• Full control over production, packaging, and labeling processes
• In-house manufacturing at CBDL facilities reduces operational costs
• Strategic positioning as U.S. manufacturer bypasses tariff and regulatory hurdles
• Potential for scalable, recurring revenue from Colombian market

Negative

• Heavy reliance on single partnership for Latin American expansion
• No specific revenue projections or financial terms disclosed
• Capital requirements for manufacturing expansion not addressed

News Market Reaction – CBDL

+25.00%

1 alert

+25.00% News Effect

On the day this news was published, CBDL gained 25.00%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

New manufacturing deal positions CBDL to tap into the $4.9 billion Latin American CBD market, unlocking major revenue growth and accelerating international expansion.

SCOTTSDALE, ARIZONA / ACCESS Newswire / April 29, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leading innovator in the cannabidiol (CBD) wellness industry, is proud to announce a major new manufacturing partnership with Thallos, a premier South American company headquartered in Colombia. Under this agreement, CBDL will take full control of the production, packaging, and labeling of a specialized line of high-potency CBD products exclusively for Thallos - a strategic move expected to significantly boost CBDL's global revenue streams.

CBDL is set to manufacture Thallos' flagship offerings, including a 2,000mg Pain Cream Salve available in both Mint and Cinnamon varieties, along with a 2,000mg CBD Tincture. These products will be produced entirely in-house at CBDL's state-of-the-art facilities, allowing the company to maintain strict quality assurance while maximizing manufacturing efficiencies.

With South America's CBD market projected to surpass $4.9 billion by 2028 and Colombia emerging as a major player, the opportunity is enormous. Due to current U.S. tariff impacts and regulatory hurdles, Colombian companies like Thallos face increasing challenges importing CBD goods. CBDL's ability to offer domestic U.S. manufacturing and distribution provides a turnkey solution, giving Thallos a competitive edge while delivering substantial new revenue for CBDL.

"This partnership is a game-changer for CBDL," said Lisa Nelson, CEO of CBD Life Sciences Inc. "By strategically positioning ourselves as the manufacturing engine for a growing South American brand, we're opening the door to scalable, recurring revenue and strengthening our position as a dominant force in the global CBD supply chain."

In addition to strengthening its financial foundation, this new international venture demonstrates CBD Life Sciences Inc.'s continued commitment to innovation, growth, and global leadership. CBDL is now uniquely positioned to leverage international partnerships, expanding its footprint into some of the fastest-growing markets in the world and setting the stage for record-breaking performance in 2025 and beyond.

About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC:CBDL) is a market-leading innovator in CBD-based wellness solutions. With a commitment to quality, consistency, and transparency, CBDL develops and distributes a broad portfolio of trusted CBD products through retail, e-commerce, and wholesale channels. For more information, visit https://thecbdvault.com/

Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Stay Connected & Be the First to Try Our New Functional Mushroom Products!

Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz

Mushroom Madness Website: https://www.mushroommadness.shop

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the value of CBDL's new Colombian manufacturing deal in 2025?

The deal positions CBDL to tap into the Latin American CBD market projected to reach $4.9 billion by 2028, with CBDL manufacturing high-potency CBD products including 2,000mg Pain Cream Salves and CBD Tinctures for Thallos.

What products will CBDL manufacture for Thallos under the 2025 partnership?

CBDL will manufacture Thallos' flagship products: 2,000mg Pain Cream Salve in Mint and Cinnamon varieties, and a 2,000mg CBD Tincture, all produced in CBDL's U.S. facilities.

How does CBDL's Colombian partnership solve Thallos' import challenges?

CBDL's U.S.-based manufacturing provides Thallos a turnkey solution to bypass Colombian companies' challenges with U.S. tariffs and regulatory hurdles when importing CBD goods.

What is the market potential for CBDL's South American expansion in 2025?

The South American CBD market is projected to exceed $4.9 billion by 2028, with Colombia emerging as a major player, offering CBDL significant revenue growth potential through its manufacturing partnership.

How will the Thallos manufacturing deal impact CBDL's revenue in 2025?

The deal is expected to provide CBDL with scalable, recurring revenue streams through exclusive manufacturing rights for Thallos' CBD products, strengthening CBDL's position in the global CBD supply chain.